tailieunhanh - báo cáo hóa học: " Health state utilities for non small cell lung cancer"

Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí hóa học quốc tế đề tài : Health state utilities for non small cell lung cancer | Health and Quality of Life Outcomes o BioMed Central Health state utilities for non small cell lung cancer Beenish Nafees 1 Megan Stafford 1 Sonia Gavriel1 Shkun Bhalla2 and Jessamy Watkins3 Address 1United BioSource Corporation UK 20 Bloomsbury Square London WC1A 2NS UK 2Former employee of Eli Lilly UK Lilly House Priestley Road Basingstoke Hampshire RG24 9NL UK and 3Eli Lilly UK Lilly House Priestley Road Basingstoke Hampshire RG24 9NL UK Email Beenish Nafees - Megan Stafford - Sonia Gavriel - Shkun Bhalla - bhalla_shkun@ Jessamy Watkins - Watkins_jessamy@ Corresponding authors Published 21 October 2008 Received 18 December 2007 Health and Quality of Life Outcomes 2008 6 84 doi 1477-7525-6-84 Accepted 21 October 2008 This article is available from http content 6 1 84 2008 Nafees et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Existing reports of utility values for metastatic non-small cell lung cancer NSCLC vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade IIIIV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia febrile neutropenia fatigue diarrhoea nausea and vomiting rash and hair loss. Methods Existing health state descriptions of metastatic breast cancer were revised to make them suitable as descriptions of metastatic NSCLC patients on second-line treatment. The existing health states were used in cognitive debrief interviews with oncologists n 5 and oncology .